Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Merck's PT-101?
PT-101 is a fusion protein commercialized by Merck, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Risk adjusted net present value: What is the current valuation of Merck's PT-101?
PT-101 is a fusion protein commercialized by Merck, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
PT-101 by Merck for Vitiligo: Likelihood of Approval
PT-101 is under clinical development by Merck and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs...